# Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

> **NCT02525679** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 78 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 655130 (spesolimab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02525679
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2016-05-27
- **Final completion:** 2016-05-27
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525679, "Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02525679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*